This study is testing an investigational injection called CM310 in 180 teenagers with moderate-to-severe eczema (atopic dermatitis). The main goal is to see how safe the treatment is and if it helps improve skin symptoms and reduce itching. All participants in this open-label stu…
Phase: PHASE3 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC